Focal Points with Brom Rector

Sam Banister is a medicinal chemist and co-founder of Psylo.  Psylo is an Australian psychedelic biotech company using machine learning assisted drug design techniques to developing novel psychedelic medicines to treat mental illness.    Sam is here to help us understand how new chemical entities are reshaping the psychedelic field; how novel psychedelic molecules are made,  and how new chemical entities are going to play a dominant role in the future of psychedelic medicine.   Make sure to subscribe to the show!   Follow Brom on twitter: https://twitter.com/therealbrom Follow Sam on twitter: https://twitter.com/samuel_b_phd Brom's VC Fund:  https://www.empath.vc Highlighted Timestamps:   06:12 - Are next generation psychedelics taking over in 10 years?   16:10 - What is the process like for creating a new chemical entities?   50:39 - Psychedelics vs Cannabis: New drug discoveries

Mendel Kaelen is the CEO of Wavepaths.  Prior to founding Wavepaths, Mendel Kaelen worked as a PhD and postdoctoral neuroscientist at Imperial College London since 2012, where his research was the one of the first to demonstrate music’s central role in psychedelic therapies.  Wavepaths is a software platform that generates personalized, optimal music for psychedelic therapy.     0:00 - Why work on music and psychedelics?  3:30 - Highlights of Mendel’s academic career.  7:30 - Is there a universal “best” music for psychedelic therapy?  How to design a psychedelic therapy playlist.  11:30 - What does the importance of music personalization mean for group psychedelic sessions?   16:00 - Should music for psychedelics be “familiar” to the patient, or novel?  20:00 - Vocals vs no vocals?  It’s not that simple.   23:00 - Directive vs non-directive and concrete vs fluid music.  25:00 - Is the “right” music for psychedelics consistent across different drugs?   28:00 - How did Mendel switch from academia to startup founder.  30:30 - What is Wavepaths?   35:30 - Who is Wavepaths for?   37:00 - How do you sell music for psychedelic therapy?   39:00 - Surprising insights from Wavepaths customers?   43:30 - How does Wavepaths use biofeedback?   46:00 - Wavepaths direct to consumer.   49:45 - Startup life vs academia.  51:00 - Virtual reality and psychedelic therapy.

Tom Feegel is the Founder and CEO of Beond.  Beond exists to help end the opiate addiction epidemic with safe ibogaine treatment.   In this episode Tom speaks on the severity of the opioid epidemic and explains how ibogaine assisted therapy can help heal those who are suffering from addiction.  Tom gets into his personal story, how Ibogaine helped someone in his family, the economics of addiction treatment and Beond's plans to scale into a global operation.     https://www.beond.us   

Dillan DiNardo is the CEO of Mindstate Design Labs - a preclinical-stage biotechnology company developing the next generation of psychedelic-inspired therapeutics for intractable mental health conditions.   Mindstate's mission is to map the biological basis of the varieties of psychedelic experience, and to use that map to pharmacologically design therapeutic states of mind to be applied in medically supervised settings to heal the root causes of mental health disorders.  Mindstate participated in Y Combinator in 2021.    Check out Mindstate @ https://www.mindstate.design/

Mental health treatment is often inaccessible, inadequate, and ineffective. However, Nue Life is working to change this through its 360-degree approach to patient health, leveraging ketamine and the integration of tech.   Check out Nue.Life here:  https://nue.life/    ⏰  Timestamps:   0:00 intro and Juan Pablo’s backstory  5:30 how Nue Life got started   11:00 the Nue Life patient experience    20:40 the intersection of data and mental health  32:30 competition in the Ketamine landscape   37:00 is ketamine addictive?   45:00 the future of at-home ketamine and the Ryan Haight act  49:15 legal psilocybin in Oregon?  53:30 what’s next for Nue Life?